Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
ABC123 trial (UCART123): what clinicians have said so far
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
- NCT03203369 ↗
- Terminated
- Cellectis S.A.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ABC123 (UCART123 in blastic plasmacytoid dendritic cell neoplasm) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ABC123 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions
- UCART123
- Arms
- Part 1: Dose Escalation · Experimental
- Part 2: Dose Expansion · Experimental
- Enrollment
- 1
- Primary outcomes
- Incidence, nature, and severity of adverse events and serious adverse events
- Sponsor
- Cellectis S.A.
- Start
- Jun 28, 2017
- Primary completion
- Jun 27, 2019
- Results posted
- No
- Registry record
- NCT03203369 · updated Jul 31, 2019